文献速递抗栓抗凝管理药物不良反应与药物警戒

左心室经皮机械循环支持患者的药理学考量

Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support.
PubMed 文献 · Pharmacotherapy · 2017-09-19

本文综述经皮机械循环支持装置(IABP、Impella、TandemHeart)用于难治性心源性休克的血流动力学支持,重点讨论抗凝管理。Impella和TandemHeart通常需肝素化冲洗液联合静脉普通肝素,提供多重肝素暴露,各有特定监测要求和目标范围。文章回顾近期证据和指南,给出装置支持期间抗凝合理使用建议,并探讨肝素化冲洗液管理、监测及非肝素抗凝剂的效用,因高质量证据有限。

要点

  • Impella和TandemHeart需肝素化冲洗液联合静脉普通肝素,存在多重肝素暴露。
  • 每种装置有特定监测要求和抗凝目标范围。
  • 非肝素抗凝剂效用证据有限,需个体化决策。

核心结论

  • 经皮机械循环支持装置(IABP、Impella、TandemHeart)用于难治性心源性休克的血流动力学支持,血栓和出血并发症常见。
  • Impella和TandemHeart有独特抗凝考量,通常需肝素化冲洗液联合静脉普通肝素,提供多重肝素暴露。
  • 每种装置有特定监测要求和目标范围,非肝素抗凝剂效用证据有限。

研究设计与样本

  • 综述,回顾近期证据和指南,总结经皮机械循环支持装置的药理学考量。

主要发现

  • Impella和TandemHeart通常需肝素化冲洗液联合静脉普通肝素,提供多重肝素暴露。
  • 每种装置有特定监测要求和目标范围。
  • 非肝素抗凝剂的效用证据有限。

临床怎么用

  • 使用Impella或TandemHeart时,应认识到肝素化冲洗液与静脉普通肝素联合导致的多重肝素暴露。
  • 遵循每种装置特定的监测要求和抗凝目标范围。
  • 非肝素抗凝剂的使用需基于有限证据个体化决策。

局限性

  • 高质量证据在文献中有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Percutaneous mechanical circulatory support (MCS) devices, including the intraaortic balloon pump, Impella, and TandemHeart, are often used for hemodynamic support in the setting of refractory cardiogenic shock. The thrombotic and bleeding complications associated with these devices is well recognized, and the Impella and TandemHeart devices have unique anticoagulation considerations that may influence patient outcomes. Both devices typically require use of a heparinized purge solution in combination with intravenous unfractionated heparin, thereby providing multiple sources of heparin exposure. Each device also has specific monitoring requirements and goal ranges. This review provides an overview of percutaneous MCS devices commonly used in the acute management of left ventricular failure, with an emphasis on pharmacologic considerations. We review recent evidence and guidelines and provide recommendations for appropriate use of anticoagulation during device support. Approaches to managing heparinized purge solutions, monitoring, and the utility of nonheparin anticoagulants are also provided because high-quality evidence in the literature is limited.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Allender JE, Reed BN, Foster JL, et al. Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support. Pharmacotherapy. 2017. PMID: 28741848. doi:10.1002/phar.1995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。